Heteroaryl sulfonamides and CCR2/CCR9

US11433061B2 · kind B2 · utility

Assignee

• CHEMOCENTRYX, INC. · US

Inventors

• Solomon Ungashe · Fremont, US
• Zheng Wei · Redwood City, US
• Arindrajit Basak · Mountain View, US
• Trevor T. Charvat · San Jose, US
• Wei Chen · Fremont, US
• Jeff Jin · Fremont, US
• Jimmie Moore · Gurnee, US
• Yibin Zeng · Foster City, US
• Sreenivas Punna · Sunnyvale, US
• Daniel Dairaghi · Palo Alto, US
• Derek Hansen · Rue de l'Église, US
• Andrew Pennell · San Francisco, US
• John J. Wright · Evansville, US
• Antoni Krasinski · San Jose, US
• Qiang Wang · Philadelphia, US

Key dates

• Filing date: Jan 10, 2020
• Grant date: Sep 6, 2022
• Expiry date: May 10, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.